Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that it has commenced an underwritten public offering of $200.0 million of its common stock.
March 1, 2021
· 3 min read